Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation
Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers
Read more from the original source:
Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million...
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced two key executive team promotions. Paratek promoted Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer.
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.
See the original post here:
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
- Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System - - Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System -
Here is the original post:
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
Chief Executive Officer Andrei Floroiu Resigns
See the original post:
Vaxart, Inc. Announces Management Change
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
Read more here:
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces the dosing of its first two patients in its Phase 1 trial testing a combination therapy for its lead therapeutic candidate ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer.
See original here:
Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung...
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of its previously announced definitive agreements with institutional investors for the purchase and sale of Common Shares and Pre-Funded Warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, Common Warrants. Aggregate gross proceeds to the Company from both transactions were approximately $2.4 million.
Read more:
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
Follow this link:
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)